News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,681 Results
Type
Article (14197)
Company Profile (282)
Press Release (252202)
Section
Business (79502)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50443)
Employer Resources (31)
FDA (5715)
Job Trends (5127)
News (144383)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21636)
ALS (61)
Alzheimer's disease (833)
Antibody-drug conjugate (ADC) (87)
Approvals (5731)
Artificial intelligence (109)
Autoimmune disease (13)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (142)
Cancer (1310)
Cardiovascular disease (112)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (307)
Cervical cancer (8)
Clinical research (40905)
Collaboration (499)
Compensation (221)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1371)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1293)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (78)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (82)
Earnings (29683)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48163)
Executive appointments (408)
FDA (6340)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (467)
Gene editing (89)
Generative AI (9)
Gene therapy (232)
GLP-1 (358)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6590)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (58)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (203)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (186)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (116)
MASH (49)
Medical device (2588)
Medtech (2589)
Mergers & acquisitions (6255)
Metabolic disorders (366)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (60)
Neuropsychiatric disorders (23)
Neuroscience (1206)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1559)
Now hiring (21)
Obesity (186)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (107)
Partnered (8)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25516)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14441)
Phase II (19033)
Phase III (12035)
Pipeline (735)
Podcasts (47)
Policy (38)
Postmarket research (852)
Preclinical (6064)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (275)
Real estate (1414)
Recruiting (12)
Regulatory (8569)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (39)
Southern California (1386)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (35)
United States (12206)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (84)
Last 7 days (450)
Last 30 days (1675)
Last 365 days (20025)
2025 (4858)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17223)
Australia (2919)
California (3545)
Canada (1055)
China (325)
Colorado (138)
Connecticut (143)
Delaware (88)
Europe (37037)
Florida (417)
Georgia (109)
Idaho (16)
Illinois (213)
India (8)
Indiana (85)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (444)
Massachusetts (2802)
Michigan (69)
Minnesota (137)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (889)
New Mexico (12)
New York (965)
North Carolina (523)
North Dakota (4)
Northern California (1559)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (678)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1386)
Tennessee (25)
Texas (410)
Utah (48)
Virginia (70)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
266,681 Results for "relmada therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and explore strategic alternatives including a potential sale to maximize shareholder value.
December 9, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
March 27, 2025
·
1 min read
Press Releases
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
March 28, 2025
·
16 min read
Press Releases
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
March 26, 2025
·
10 min read
Press Releases
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
February 6, 2025
·
7 min read
Press Releases
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
November 19, 2024
·
1 min read
Press Releases
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
December 9, 2024
·
4 min read
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat on Thursday, June 6, 2024, at 7:30am ET at the 2024 Jefferies Global Healthcare Conference in New York, NY.
June 3, 2024
·
4 min read
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Relmada Therapeutics, Inc. today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry.
June 18, 2024
·
5 min read
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Relmada Therapeutics, Inc. today announced that they will participate in the Leerink Partners Global Biopharma Conference.
March 5, 2024
·
3 min read
1 of 26,669
Next
